Binnopharm Collaborates with Mabell to Produce MAB in Russia
Published: 11 Feb 2026
Author: Precedence Research
Russian pharmaceutical company Binnopharm Group has collaborated with Chinese biopharma company Mabwell for the production of monoclonal antibodies in Russia. This partnership is an extension of the agreement according to which Binnopharm acquired exclusive rights to develop, register, manufacture and sell some of Mabwell’s biosimilars such as denosumab and adalimumab.
These are biosimilar versions of the top global drugs, specifically adalimumab which is commonly known by its trade name Humira, is used for autoimmune conditions such as arthritis and psoriasis. On the other hand, denosumab is used for the treatment and prevention of osteoporosis among cancer patients. Under this initiative, the companies are also looking into the development of advanced monoclonal antibody drugs. A full cycle bioproduction facility has been set up in Zelenograd. It encompasses all the processes from cell lines through to final drugs.
This step would also strengthen Russia’s biopharmaceutical manufacturing industry. This facility is intended to manufacture locally produced high quality biologics for Russian and EAEU markets. Mabwell will contribute with their experience in the development of medicine and biosimilars. Binnopharm adds local regulatory, manufacturing and marketing capabilities. This partnership aims to reduce costs and increase access to essential medicines.
Th first product launch plans involve biosimilars for the treatment of rheumatoid arthritis and osteoporosis, with marketing authorizations and sales starting in early 2026.Industry analysts have described this partnership as being in line with the broader landscape of enhancing local bioscience manufacturing in emerging markets. This will result in reduced dependence on imports and affordable medicines costs for the citizens.
We focus exclusively on this industry and provide insights that help you make better decisions. Get in touch to learn more@ https://www.precedenceresearch.com/active-pharmaceutical-ingredient-market